Soligenix completes FLASH2 study with 50 patients, exceeds trial estimate.
ByAinvest
Wednesday, Nov 19, 2025 7:35 am ET1min read
SNGX--
Soligenix has completed enrollment of 50 patients in its Phase 3 study (FLASH2) evaluating HyBryte (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL). The interim analysis of the blinded response rate exceeds the trial estimate. HyBryte has shown promising results in previous studies, including a statistically significant Phase 3 study and a comparative study. The company is focused on developing and commercializing products for rare diseases where there is an unmet medical need.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet